Sysmex (OTCMKTS:SSMXY) Trading Down 7% – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price fell 7% on Wednesday . The stock traded as low as $11.70 and last traded at $11.70. Approximately 1,555 shares traded hands during trading, a decline of 99% from the average session volume of 210,893 shares. The stock had previously closed at $12.5750.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Sysmex Price Performance

The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm has a market cap of $7.69 billion, a price-to-earnings ratio of 29.07 and a beta of 1.05. The company’s 50-day moving average is $9.52 and its 200-day moving average is $9.11.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The business had revenue of $825.85 million during the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Equities research analysts predict that Sysmex Corporation ADR will post 0.38 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.